BofA analyst Greg Harrison raised the firm’s price target on IGM Biosciences to $9.50 from $8 and keeps a Neutral rating on the shares after the company provided a “positive” corporate update at a recent healthcare conference. The firm sees recent strength in the stock as likely due to the addition of well-known investors and looks for derisking data updates to continue to re-evaluate the company, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on IGMS:
- IGM Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Chimerix appoints Lisa Decker to board of directors
- Biotech Alert: Searches spiking for these stocks today
- IGM Biosciences just downgraded at BofA, here’s why
- IGM Biosciences downgraded to Neutral from Buy at BofA
Questions or Comments about the article? Write to editor@tipranks.com